Genetic Control of Wayward Pluripotent Stem Cells and Their Progeny after Transplantation

Maija Ht Kiuru; Julie L. Boyer; Timothy P. O'Connor; Ronald G. Crystal

doi:10.1016/j.stem.2009.03.010

Genetic Control of Wayward Pluripotent Stem Cells and Their Progeny after Transplantation

Maija Ht Kiuru, Julie L. Boyer, Timothy P. O'Connor, Ronald G. Crystal

Research output: Contribution to journal › Review article › peer-review

60 Scopus citations

Abstract

The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.

Original language	English (US)
Pages (from-to)	289-300
Number of pages	12
Journal	Cell Stem Cell
Volume	4
Issue number	4
DOIs	https://doi.org/10.1016/j.stem.2009.03.010
State	Published - Apr 3 2009
Externally published	Yes

ASJC Scopus subject areas

Cell Biology
Molecular Medicine
Genetics

Access to Document

10.1016/j.stem.2009.03.010

Fingerprint Dive into the research topics of 'Genetic Control of Wayward Pluripotent Stem Cells and Their Progeny after Transplantation'. Together they form a unique fingerprint.

Cite this

@article{ce3a0c666fad460d95ba6a2b8d8dbf87,

title = "Genetic Control of Wayward Pluripotent Stem Cells and Their Progeny after Transplantation",

abstract = "The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.",

author = "Kiuru, {Maija Ht} and Boyer, {Julie L.} and O'Connor, {Timothy P.} and Crystal, {Ronald G.}",

year = "2009",

month = apr,

day = "3",

doi = "10.1016/j.stem.2009.03.010",

language = "English (US)",

volume = "4",

pages = "289--300",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "4",

}

TY - JOUR

T1 - Genetic Control of Wayward Pluripotent Stem Cells and Their Progeny after Transplantation

AU - Kiuru, Maija Ht

AU - Boyer, Julie L.

AU - O'Connor, Timothy P.

AU - Crystal, Ronald G.

PY - 2009/4/3

Y1 - 2009/4/3

N2 - The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.

AB - The proliferative capacity of pluripotent stem cells and their progeny brings a unique aspect to therapeutics, in that once a transplant is initiated the therapist no longer has control of the therapy. In the context of the recent FDA approval of a human ESC trial and report of a neuronal-stem-cell-derived tumor in a human trial, strategies need to be developed to control wayward pluripotent stem cells. Here, we focus on one approach: direct genetic modification of the cells prior to transplantation with genes that can prevent the adverse events and/or eliminate the transplanted cells and their progeny.

UR - http://www.scopus.com/inward/record.url?scp=62949195751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62949195751&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2009.03.010

DO - 10.1016/j.stem.2009.03.010

M3 - Review article

C2 - 19341619

AN - SCOPUS:62949195751

VL - 4

SP - 289

EP - 300

JO - Cell Stem Cell

JF - Cell Stem Cell

SN - 1934-5909

IS - 4

ER -